Genomic newborn screening: ICoNS

Gene: GAMT

Green List (high evidence)

GAMT (guanidinoacetate N-methyltransferase)
EnsemblGeneIds (GRCh38): ENSG00000130005
EnsemblGeneIds (GRCh37): ENSG00000130005
OMIM: 601240, Gene2Phenotype
GAMT is in 14 panels

2 reviews

Zornitza Stark (Victorian Clinical Genetics Services)

Green List (high evidence)

ICoNS Gene List Subcommittee meeting 17/09/2025.

Condition is included in the RUSP panel.

Additional information: https://creatineinfo.org/screening/

Consensus decision this gene-disease pair should be included.
Created: 17 Sep 2025, 6:35 a.m. | Last Modified: 17 Sep 2025, 6:35 a.m.
Panel Version: 0.11

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Cerebral creatine deficiency syndrome 2, MIM#612736

Judit Garcia (Other)

Green List (high evidence)

Broad review of CCDS biology/phenotypes including GAMT. Mulik et al., Children (Basel), 2023.

The condition is treatable when identified early (creatine supplementation, dietary management). Treatment: Oral creatine monohydrate to replenish cerebral creatine plus arginine restriction and L-ornithine supplementation to reduce GAA; best outcomes with early initiation. https://www.ncbi.nlm.nih.gov/books/NBK3794/?utm_source=chatgpt.com; Stockler-Ipsiroglu et al., Mol Genet Metab, 2014.

There is good evidence of GREEN in other panel of gens: Mendeliome, Genetic Epilepsy, Intellectual Disability, Dystonia – complex, Reproductive Carrier Screening, Metabolic Disorders, Newborn screening panels, etc.

Only in RED in Cerebral Palsy, Fetal anomalies.

Evidence sources: Expert Review Green, NHS GMS, Victorian Clinical Genetics Services, Australian Genomics Health Alliance Epilepsy Flagship.

There is a biochemical test to confirm pathogenicity of variants detected. Pathogenic variants: Increased Guanidinoacetic acid (GAA) in urine, plasma and dired blood spot; brain MRS with reduced creatine.

There is a definitive gene–disease validity (ClinGen); use CCDS VCEP ACMG/AMP specifications for variant classification in clinical reporting.
Created: 9 Sep 2025, 12:39 a.m. | Last Modified: 9 Sep 2025, 12:40 a.m.
Panel Version: 0.7
Sources: Expert Review
Created: 9 Sep 2025, 12:18 a.m.

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Creberal creatine deficiency syndrome 2 (MIM 612736); global developmental delay; intellectual disability; epilepsy; behavioral disturbance; movement disorder; markedly low brain creatine and elevated guanidinoacetate.

Publications

Variants in this GENE are reported as part of current diagnostic practice

History Filter Activity

17 Sep 2025, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services)

Gene: gamt has been classified as Green List (High Evidence).

17 Sep 2025, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services)

Publications for gene: GAMT were set to

17 Sep 2025, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services)

Gene: gamt has been classified as Green List (High Evidence).

9 Sep 2025, Gel status: 0

Created, Added New Source, Set mode of inheritance, Set Phenotypes, Set penetrance

Judit Garcia (Other)

gene: GAMT was added gene: GAMT was added to Genomic newborn screening: ICoNS. Sources: Expert Review Mode of inheritance for gene: GAMT was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: GAMT were set to Creberal creatine deficiency syndrome 2 (MIM 612736) Penetrance for gene: GAMT were set to Complete Review for gene: GAMT was set to GREEN gene: GAMT was marked as current diagnostic